Cell line · CVCL_0529
Papers41
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 41
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The Host Cell Factor Phosphatase-2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type-1. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| QW-5-70 Targets the Colchicine Site and Demonstrates Antitumor Activity in P-gp-Overexpressing Cancer Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LMO1 expression in neuroblastoma cells reprograms tumor-associated macrophages to promote metastasis. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Cas9 screening develops an epigenetic and transcriptional gene signature for risk stratification and target prediction in neuroblastoma. | Front Cell Dev Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| L-Glyceraldehyde Inhibits Neuroblastoma Cell Growth via a Multi-Modal Mechanism on Metabolism and Signaling. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Atlas of primary cell-type-specific sequence models of gene expression and variant effects. | Cell Rep Methods | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer cells. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface. | Commun Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Int J Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. | Nat Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Identification and characterization of novel candidate compounds targeting 6- and 7-transmembrane μ-opioid receptor isoforms. | Br J Pharmacol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0529/papers